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Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by extensive immune response, including over-activation of T and B cell development of pathogenic autoantibodies, organ damage induced by the formation and deposition of immune complex and the abnormal elevation of type I interferon. Semaphorin5A (Sema5A) is involved essentially in immune cell regulation and is also implicated in the pathogenesis of autoimmune disorders. We aimed to evaluate the role of Sema5A in patients with SLE. Serum levels of Sema5A were tested by enzyme-linked immunosorbent assay (ELISA) in 152 SLE patients and 48 healthy controls. The message ribonucleic acid (mRNA) expression levels of Sema5A and ADAM metallopeptidase domain 17 (ADAM17) in the peripheral blood mononuclear cells (PBMC) from 43 patients with SLE and 19 healthy controls were detected by the real-time-quantitative polymerase chain reaction (qPCR). Serum Sema5A levels were increased significantly in SLE patients compared with healthy controls (P < 0Á001). Elevated levels of Sema5A were correlated positively with 24-h proteinuria excretion (r 5 0Á558, P < 0Á0001), SLE disease activity index (SLEDAI) (r 5 0Á278,
Introduction
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, which can result in skin rashes, arthritis, leucopenia, nephritis and inflammation of the nervous system [1] . Immunologically, SLE is characterized by high B cell reactivity and production of autoantibodies to nuclear and cytoplasmic components [2] , and sustained production of autoantibodies leads to the accumulation of immune complex in kidney [3] , brain [4] and other organs.
SLE begins with self-tolerance loss and the presence of autoreactive lymphocytes in the peripheral blood, due to both environmental and genetic factors [5, 6] . Multiple types of cells and cytokines in the adaptive and innate immune system have been confirmed to contribute to SLE pathogenesis.
Semaphorins are a large family (classified into eight subclasses) of secreted and membrane-bound proteins, discovered originally in the nervous system, which are involved in repulsive axon guidance during nervous system development [7] . They are related to two families of receptors: the neuropilins (NP-1 and NP-2), as the primary ligand binding sites and plexins, as the signal transducing components. Several of members of the semaphorin family, the so-called 'immune semaphorins' , including semaphorin3A (Sema3A), Sema4D, Sema6D and Sema7A, are involved essentially in immune cell regulation [8] and are also implicated in the pathogenesis of autoimmune disorders [9] [10] [11] .
Sema5A, as a membrane-bound member of this family, comprises transmembrane protein that exhibits a unique extracellular domain containing seven thrombospondinspecific repeats in addition to the sema domain [12] . Receptors for Sema5A are plexin proteins, including plexin-A1 and plexin-B3 [13, 14] . Previously, a soluble form of Sema5A was described [15] . It has been described to promote angiogenesis by increasing endothelial cell proliferation and decreasing apoptosis [16] ; elevated expression levels of Sema5A were associated with high tumorigenic and metastatic potentials in pancreatic and gastric tumours [17] [18] [19] . Moreover, further studies revealed Sema5A to be an immune semaphorin for its role in innate immune responses by inducing the expression of tumour necrosis factor (TNF) and interleukin (IL)28 genes [15, 20] .
With respect to the significant role of secreted Sema5A in innate immunity, increasing attention has been paid to its immune regulation in autoimmune diseases. A recent study showed that significantly elevated levels of secreted Sema5A were detected in the serum of patients with rheumatoid arthritis (RA) and other autoimmune diseases compared with control serum. Soluble Sema5A greatly promoted T cell and natural killer (NK) cell proliferation and induced the secretion of T helper type 1 (Th1)/Th17 proinflammatory cytokines [21] . In another study, the researchers found that plasma levels of Sema5A were increased significantly in patients with active chronic immune thrombocytopenic purpura (ITP). In addition, plasma levels of Sema5A were correlated negatively with platelet counts in active patients. Therefore, it is plausible that Sema5A might be in positive correlation with disease activity [22] . In consideration of the above, we initiated this study to assess the possible role of Sema5A in systemic lupus erythematosus (SLE); that is, to measure its serum level in SLE patients and assess whether this level correlates with disease status.
Materials and methods

Patients and controls
A total of 152 patients with SLE and 48 healthy controls were enrolled at the Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University School of Medicine, and blood samples were obtained from these patients. The diagnosis of SLE was based on the American College of Rheumatology (ACR) 1997 revised classification criteria [23] . Healthy controls were recruited from healthy staff members of the hospital. Prior to enrolment, all participants signed the informed consent to donate their blood samples and their clinical information was de-identified for research. Our study was approved by the ethics committee of the Second Affiliated Hospital of Zhejiang University School of Medicine. The mRNA detection was performed from 43 of 152 patients and 19 of 48 healthy controls.
Clinical data analysis
General and laboratory data were collected from the medical records of these patients, including age, gender, disease duration, clinical symptoms, blood cell counts [leucocyte: white blood cells (WBC); platelets (PLT): thrombocyte], routine chemistry, urinalysis, 24-h proteinuria excretion, lupus-associated antoantibodies [anti-double-strand DNA antibody (anti-dsDNA antibody); anti-nuclear antibody (ANA); anti-nucleosome antibody (AnuA); anti-SSA antibody (SSA); anti-Sm antibody (Sm); anti-cardiolipin antibody (aCL), immunoglobulins (IgG, IgM, IgA), complement component3 (C3), complement component 4 (C4), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)]. White cell and planet counts of less than 4 310 9 /l and 100 3 10 9 /l were regarded as leucocytopenia and thrombocytopenia, respectively. Proteinuria was defined as 24-h proteinuria excretion more than or equal to 0Á5 g. Anti-dsDNA antibody, ACL, AnuA, C3, C4, IgG, IgM and IgA were tested by enzyme-linked immunosorbent assay (ELISA), with normal ranges of 0-100 IU/ml, 0-12 RU/ml, 0-20 RU/ml, 0Á82-1Á8 g/l, 100-400 mg/l, 7-16 g/l, 0Á4-2Á3 g/l and 0Á7-4 g/l. ANA, SSA and Sm were tested by indirect immunofluorescence assay. Positive autoantibodies of anti-dsDNA antibody, aCL and AnuA were defined as values more than 100 IU/ml, 12 RU/ml and 20 RU/ml, respectively. Decreased C3 and C4 were defined as values less than 0Á82 g/l and 100 mg/l. CRP was examined using the immunonephelometry method. Values more than or equal to 10 mg/l were considered positive. ESR were measured by Westergren's method, with values > 15 mm/h for men and > 20 mm/h for women considered abnormal.
Disease activity was calculated by using the SLE disease activity index (SLEDAI) [24] . Clinical features defined by the SLEDAI system were seizure, psychiatric symptoms, encephalosis, visual injury, cranial neuropathy, lupus headache, cerebrovascular insult, vasculitis arthritis, myositis, cylindruria [haemoglobin red blood cell (HbRBC) cylinder, granular cast], haemoglobinuria (> 5RBC/haptoglobin (HP)], pyuria (> 5WBC/HP), leucocytopenia and thrombocytopenia.
Enzyme-linked immunosorbent assay (ELISA)
All serum samples were split into aliquots and stored at 2808C until use. ELISA kits (JYM2074Hu) were used for measuring levels of Sema5A in serum (Jiyinmei, Wuhan, China), according to the manufacturer's instructions. The difference in intra-and interassay is less than 9 and 15%, respectively.
RNA isolation and quantitative real-time-polymerase chain reaction (RT-PCR) analysis
Forty-three SLE patients and 19 healthy controls were assessed for Sema5A and ADAM metallopeptidase domain 17 (ADAM17) mRNA expression in peripheral blood mononuclear cells (PBMCs). Cells were harvested and total RNA was extracted from PBMCs using an RNA extraction kit (Tiangen, Beijing, China). The cDNA was synthesized according to the instructions indicated in a RevertAid TM first-strand cDNA synthesis kit (Fermentas, Shenzhen, China). For real-time PCR, two-step PCR was performed using Power SYBR V R Green PCR Master Mix (Applied Biosystems, Beijing, China), according to the manufacturer's instructions. The sequences of the amplification primers were as follows -Sema5A: forward:
0 ; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward: 5 0 -AAGGTGAAGGTCGGAGTC AA-3 0 , reverse: 5 0 -AATGAAGGGGTCATTGATGG-3 0 . The reaction was run on the 7500 Fast Real-time PCR System (Applied Biosystems). Gene expression was quantified relative to the expression of the housekeeping gene, GAPDH, and normalized to control by standard 2 -᭝᭝CT calculation.
Statistical analyses
Data analyses were performed using SPSS software for Windows version 16.0. For normally distributed data expressed as mean values 6 standard deviation (s.d.), differences between groups were analysed using Student's t-test. Comparisons of categorical variables were conducted using Pearson's v 2 tests. For non-parametric data, results were expressed as median (range) values, and the differences between groups were analysed by the Mann-Whitney Utest. Pearson's correlation coefficient was applied to detect the correlation between two groups. P-values less than 0Á05 were considered significant. 
Results
Clinical and demographic features
Demographic and clinical characteristics of SLE patients and healthy controls are shown in Table 1 . One hundred and fifty-two SLE patients and 48 age-and gendermatched controls were recruited into this study (age, 37Á42 6 14Á73 versus 37Á05 6 14Á51, P 5 0Á1; gender, v 2 5 0Á15, P 5 0Á69). The SLE patients had a median disease duration of 48 months, ranging from 1 to 480, and the mean SLEDAI scores of these patients was 9Á21, ranging from 0 to 32. Serum Sema5A levels in SLE patients and controls
Serum Sema5A levels were significantly higher in patients with SLE (9Á48 6 0Á77 ng/ml) than in healthy controls (2Á93 6 0Á34ng/ml, P < 0Á0001, Fig. 1a ). The concentrations of serum Sema5A were identified to be correlated positively with age and disease duration (for age: r 5 0Á244, P 5 0Á0028; for disease duration: r 5 0Á213, P 5 0Á0085) (Fig. 1b, c) .
Increased serum Sema5A levels were associated with increased activity and severe clinical manifestations in SLE
In patients with SLE, there was a weak but significant positive correlation between serum Sema5A levels and SLEDAI score (r 5 0Á278, P 5 0Á0006) (Fig. 2a , Table 2 ). The concentrations of serum Sema5A were also found to be correlated positively with 24-h proteinuria excretion (r 5 0Á558, P < 0Á0001) and CRP (r 5 0Á266, P 5 0Á002) ( Table 2 , Fig.  2a ), but negatively with PLT (r 5 -0Á294, P 5 0Á0003) and C3 (r 5 -0Á287, P 5 0Á0004) ( Table 2 , Fig. 2a ) in SLE patients, which implied that patients with elevated Sema5A levels were prone to develop more severe inflammation or symptoms such as thrombocytopenia and proteinuria. Other laboratory data, including leucocyte number, C4 level, IgA, IgG, IgM, ESR and anti-dsDNA antibody, did not show a significant correlation with serum Sema5A levels (Table 2) . We compared further the serum Sema5A levels between patients with and without particular clinical features. In SLE patients with SLEDAI ! 10, serum Sema5A levels were significantly higher than those with SLEDAI < 10 (12Á23 6 1Á44 ng/ml versus 8Á05 6 0Á86 ng/ml, P 5 0Á0034). Serum Sema5A was elevated significantly in patients with nephritis, more 24-h proteinuria excretion, thrombocytopenia or decreased C3 than without (with lupus nephritis: 13Á14 6 1Á32 ng/ml versus without lupus nephritis: 6Á96 6 0Á83 ng/ ml, P < 0Á0001; proteinuria excretion ! 0Á1 g: 14Á02 6 1Á39 ng/ml versus proteinuria excretion < 0Á1 g: 6Á85 6 0Á85 ng/ml, P < 0Á0001; with thrombocytopenia: 14Á33 6 2Á12 ng/ml versus without thrombocytopenia: 8Á21 6 0Á77 ng/ml, P 5 0Á0026; decreased C3: 10Á15 6 0Á89 ng/ml versus normal 7Á35 6 1Á44 ng/ml, P 5 0Á036) (Fig. 2b) . In summary, elevated Sema5A levels in serum were associated significantly with increased SLE disease activity and severity.
Comparison of clinical features between Sema5A-positive and -negative SLE patients
The cut-off value for positivity was established as 2 s.d. above the mean value for healthy controls. Among the 152 patients with SLE, there were no significant differences between the Sema5A-positive and -negative subgroups with respect to sex, autoantibodies and most other features (Table 3) . However, the Sema5A-positive group showed a higher incidence of rash (17 of 64 versus 37 of 88; P 5 0Á048), serositis (19 of 64 versus six of 88; P < 0Á001) and nephritis (37 of 64 versus 25 of 88; P < 0Á001) compared with the Sema5A-negative group. Moreover, the values of age, disease duration, SLEDAI and CRP were significantly higher in the Sema5A-positive group compared with the Sema5A-negative group (age: 41Á79 6 16Á36 versus 33Á92 6 12Á47; P 5 0Á002; disease duration: 60 (1-480) versus 30 (1-360); P 5 0Á003; SLEDAI: 10Á50 6 7Á02 versus 8Á26 6 5Á59; P 5 0Á038; CRP: 6Á6 (0Á1-334Á7) versus 2 (0Á1-93Á1); P 5 0Á013;), but the values of IgG, C3 and PLT counts were lower in the Sema5A-positive group compared with the Sema5A-negative group (IgG: 13Á61 (2Á75-29Á6) versus 16Á3 (5Á85-52Á4); P 5 0Á023; C3: 0Á52 6 0Á26 versus 0Á65 6 0Á31; P 5 0Á007; PLT count: 130 (10-339) versus 171Á5 (5-196); P < 0Á001). (Table 3 ).
The mRNA expression of Sema5A and ADAM17 in PBMCs of SLE patients Sema5A and ADAM17 mRNA expression were detected in both SLE patients and healthy controls. Inconsistent with serum Sema5A levels, quantitative RT-PCR analysis showed that there was no significant difference in Sema5A mRNA expression between SLE patients and healthy controls (2Á55 6 0Á76 versus 1Á07 6 0Á19; P > 0Á05, Fig. 3a) . The ADAM17 mRNA level in PBMC was significantly higher in SLE patients than in healthy controls (13Á20 6 1Á40 versus 1Á37 6 0Á31, P < 0Á0001; Fig. 3b ). There was a positive correlation between ADAM17 mRNA and serum Sema5A levels (r 5 0Á86, P 5 0Á024; Fig. 4) . 
Discussion
The semaphorins were discovered originally in the nervous system, where they have been involved in repulsive axon guidance during nervous system development [25, 26] . They are a large family (classified into eight subclasses) of secreted and membrane-bound proteins, Fig. 3 . The mRNA expression of semaphorin5A (Sema5A) and ADAM metallopeptidase domain 17 (ADAM17) in peripheral blood mononuclear cells (PBMC) systemic lupus erythematosus (SLE) SLE patients. (a) There was no significant difference in Sema5A mRNA expression between SLE patients and healthy controls. (b) The ADAM17 mRNA level in peripheral blood mononuclear cells (PBMCs) was significantly higher in SLE patients than in healthy controls. [27] .
In recent years, there has been a large growing body of data regarding the involvement of semaphorins in the regulation of the immune system ('immune semaphorins'). They were found in the microenvironmental cells of the developing murine thymus, suggesting that they are involved in the guidance of T precursor cells into the thymus by chemorepulsion [28] .
Several semaphorin members were found in association with autoimmune diseases. The expression of the Sema4D molecule on peripheral blood lymphocytes of lupus nephritis patients correlated with clinical status [29] . Altered serum Sema3A levels were found to be in inverse correlation with SLE disease activity, mainly with renal damage and the presence of anti-cardiolipin antibodies; it has a regulatory mode of action, with proven abilities of decreasing Toll-like receptor (TLR)29 expression in memory B cells of SLE patients [30, 31] .
As one of the semaphorin family members, Sema5A and its receptors were characterized originally as constituents of the complex regulatory system responsible for the wiring of neural networks during the development of the central nervous system, and were found subsequently to participate in activities outside the nervous system, such as migration of neural crest cells and heart development, to name but a few examples. A recent study suggested a role for Sema5A in innate immune signalling pathways during mastitis in dairy cows. Moreover, Sema5A potently modulate immune cell responses in relation to disease activity in RA and ITP patients.
Deregulation of innate immunity and clearance of apoptotic cells have been implicated in the pathogenesis of SLE [32, 33] . In SLE, cell debris produced by impaired apoptosis may serve as danger signals to break immune tolerance and result in autoimmune inflammation and autoantibody production [34] . In this study, we demonstrated for the first time, to our knowledge, that serum levels of Sema5A were increased significantly in SLE patients compared with healthy controls (P < 0Á001). Serum levels of Sema5A were correlated positively with 24-h proteinuria excretion (r 5 0Á558, P < 0Á0001), SLEDAI (r 5 0Á278, P < 0Á001) and CRP (r 5 0Á266, P 5 0Á002), but negatively with PLT (r 5 -0Á294, P < 0Á001) and C3 (r 5 -0Á287, P < 0Á001) in SLE patients. Taken together, these results demonstrate that Sema5A might play an important role in the development of SLE.
In terms of clinical and laboratory variables, Sema5A-positive and negative SLE patients were similar, with the notable exception that the Sema5A-positive group showed a higher incidence of rash, serositis and nephritis compared with the Sema5A-negative group. Moreover, the values of age, disease duration, SLEDAI and CRP were significantly higher in the Sema5A-positive group than the Sema5A-negative group, but the values of IgG, C3 and PLT counts were lower in the Sema5A-positive than the Sema5A-negative group.
Evidence of elevated Sema5A expression has been reported in PBMCs at the RNA level, suggesting that PBMCs might be a major source of secreted Sema5A [21] . In our study, contrary to increased serum Sema5A levels in SLE patients, Sema5A mRNA expression in PBMCs was not up-regulated significantly, which indicated that increased soluble Sema5A did not result from Sema5A expression, but was associated with more protein off to serum. Membrane Sema5A was reported to be shed into soluble forms through ADAM-17-dependent cleavage and circulated in plasma. Our study showed clearly that ADAM17 expression in PBMCs was correlated positively with Sema5A levels in serum, which might explain the inconsistency between the serum levels of Sema5A and the mRNA expression of Sema5A in our study.
To demonstrate further that increased serum levels of sema5A are due to increased shedding, we assessed the expression of Sema5A on the membrane of PBMCs and compared this between SLE and healthy controls. Western blot analysis showed that membrane Sema5A levels were decreased significantly in SLE patients compared with healthy controls (ratio of Sema5A/Na/K ATPase SLE: 0Á29 6 0Á14; HC: 1Á17 6 0Á62, P < 0Á001, Supporting information, Fig. S1 ), which indicated that increased serum levels of Sema5A in SLE patients rely upon increased shedding.
In conclusion, although our results stem from a singlecentre study with a relatively small sample size that could bias the association between Sema5A and SLE, we present initial evidence that serum Sema5A increased significantly in SLE and correlated positively with disease activity and severity. The up-regulation of serum Sema5A may serve as a biomarker of disease activity and severity of SLE. Further investigation into the exact role of Sema5A signalling will provide novel insights into the pathogenesis of SLE.
Supporting information
Additional Supporting information may be found in the online version of this article at the publisher's website. Fig. S1 . Decreased membrane semaphorin5A (Sema5A) on peripheral blood mononuclear cells (PBMCs) in patients with systemic lupus erythematosus (SLE) was detected. Membrane protein was extracted from the PBMCs of 11 SLE patients and 11 healthy controls. Sema5A protein expression levels were detected using Western blot. Na/K ATPase was used as a protein loading control. A set of random data from six SLE patients and six healthy controls is presented (P < 0Á001).
